

## Erratum to: Could Metabolic Therapy Become a Viable Alternative to the Standard of Care for Managing Glioblastoma?

Thomas N Seyfried, PhD,<sup>1</sup> Jeremy Marsh, MSV,<sup>2</sup> Purna Mukherjee, PhD,<sup>3</sup> Giulio Zuccoli, MD<sup>4</sup> and Dominic P D’Agostino, PhD<sup>5</sup>

1. Professor of Biology; 2 Bachelor of Science; 3. Research Assistant Professor, Biology Department, Boston College, Chestnut Hill, Massachusetts, US; 4. Section Chief, Section of Neuroradiology, Children’s Hospital of Pittsburgh, and Associate Professor of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, US; 5. Assistant Professor, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, US

**Citation:** *Oncology & Hematology Review*, 2014;10(2):i [online only]

**Erratum to:** *Oncology & Hematology Review*, 2014;10(1):13–20


In order to comply with the latest recommendations outlined by ICMJE the publisher would like to make the following amendments to the Disclosure section:

Thomas N Seyfried, PhD, Jeremy Marsh, MSV, Purna Mukherjee, PhD, Giulio Zuccoli, MD and Dominic P D’Agostino, PhD have no conflicts of interest to declare.

The publisher and authors would like to make the following adjustments to *Figure 1* in the article.

The Red line in the figure should be labelled Radiotherapy, and the Blue line should be labelled Combined. Also, the P value should be  $P < 0.0001$ .

In the legend, the patient numbers should read radiotherapy alone  $n=286$  and combined  $n=287$ .



The two patient groups included radiotherapy alone ( $n=286$ ) and radiotherapy with temolozomide ( $n=287$ ). Overall patient survival has remained largely unchanged from the study published in 2005.<sup>45</sup> Reprinted with permission from Stupp et al.<sup>3</sup>